152 related articles for article (PubMed ID: 38428307)
1. Improvement of NASH and liver fibrosis through modulation of the gut-liver axis by a novel intestinal FXR agonist.
Moon AN; Briand F; Breyner N; Song DK; Madsen MR; Kim H; Choi K; Lee Y; Namkung W
Biomed Pharmacother; 2024 Apr; 173():116331. PubMed ID: 38428307
[TBL] [Abstract][Full Text] [Related]
2. Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH).
Fiorucci S; Biagioli M; Sepe V; Zampella A; Distrutti E
Expert Opin Investig Drugs; 2020 Jun; 29(6):623-632. PubMed ID: 32552182
[TBL] [Abstract][Full Text] [Related]
3. Dysregulated FXR-FGF19 signaling and choline metabolism are associated with gut dysbiosis and hyperplasia in a novel pig model of pediatric NASH.
Hernandez GV; Smith VA; Melnyk M; Burd MA; Sprayberry KA; Edwards MS; Peterson DG; Bennet DC; Fanter RK; Columbus DA; Steibel JP; Glanz H; Immoos C; Rice MS; Santiago-Rodriguez TM; Blank J; VanderKelen JJ; Kitts CL; Piccolo BD; La Frano MR; Burrin DG; Maj M; Manjarin R
Am J Physiol Gastrointest Liver Physiol; 2020 Mar; 318(3):G582-G609. PubMed ID: 32003601
[TBL] [Abstract][Full Text] [Related]
4. INT-767 improves histopathological features in a diet-induced
Roth JD; Feigh M; Veidal SS; Fensholdt LK; Rigbolt KT; Hansen HH; Chen LC; Petitjean M; Friley W; Vrang N; Jelsing J; Young M
World J Gastroenterol; 2018 Jan; 24(2):195-210. PubMed ID: 29375205
[TBL] [Abstract][Full Text] [Related]
5. The role of FXR and TGR5 in reversing and preventing progression of Western diet-induced hepatic steatosis, inflammation, and fibrosis in mice.
Wang XX; Xie C; Libby AE; Ranjit S; Levi J; Myakala K; Bhasin K; Jones BA; Orlicky DJ; Takahashi S; Dvornikov A; Kleiner DE; Hewitt SM; Adorini L; Kopp JB; Krausz KW; Rosenberg A; McManaman JL; Robertson CE; Ir D; Frank DN; Luo Y; Gonzalez FJ; Gratton E; Levi M
J Biol Chem; 2022 Nov; 298(11):102530. PubMed ID: 36209823
[TBL] [Abstract][Full Text] [Related]
6. A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis.
Harrison SA; Bashir MR; Lee KJ; Shim-Lopez J; Lee J; Wagner B; Smith ND; Chen HC; Lawitz EJ
J Hepatol; 2021 Jul; 75(1):25-33. PubMed ID: 33581174
[TBL] [Abstract][Full Text] [Related]
7. Hammerhead-type FXR agonists induce an enhancer RNA
Chen J; Wang R; Xiong F; Sun H; Kemper B; Li W; Kemper J
Elife; 2024 Apr; 13():. PubMed ID: 38619504
[TBL] [Abstract][Full Text] [Related]
8. FXR and NASH: an avenue for tissue-specific regulation.
Henry Z; Meadows V; Guo GL
Hepatol Commun; 2023 May; 7(5):. PubMed ID: 37058105
[TBL] [Abstract][Full Text] [Related]
9. Salidroside improves high-fat diet-induced non-alcoholic steatohepatitis by regulating the gut microbiota-bile acid-farnesoid X receptor axis.
Li H; Xi Y; Xin X; Tian H; Hu Y
Biomed Pharmacother; 2020 Apr; 124():109915. PubMed ID: 31986416
[TBL] [Abstract][Full Text] [Related]
10. Sodium cholate ameliorates nonalcoholic steatohepatitis by activation of FXR signaling.
Pan L; Yu Z; Liang X; Yao J; Fu Y; He X; Ren X; Chen J; Li X; Lu M; Lan T
Hepatol Commun; 2023 Feb; 7(2):e0039. PubMed ID: 36706173
[TBL] [Abstract][Full Text] [Related]
11. Ursodeoxycholic acid is a GPBAR1 agonist and resets liver/intestinal FXR signaling in a model of diet-induced dysbiosis and NASH.
Carino A; Biagioli M; Marchianò S; Fiorucci C; Zampella A; Monti MC; Scarpelli P; Ricci P; Distrutti E; Fiorucci S
Biochim Biophys Acta Mol Cell Biol Lipids; 2019 Oct; 1864(10):1422-1437. PubMed ID: 31325638
[TBL] [Abstract][Full Text] [Related]
12. The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Chow MD; Lee YH; Guo GL
Mol Aspects Med; 2017 Aug; 56():34-44. PubMed ID: 28442273
[TBL] [Abstract][Full Text] [Related]
13. Proglumide Reverses Nonalcoholic Steatohepatitis by Interaction with the Farnesoid X Receptor and Altering the Microbiome.
Gay MD; Cao H; Shivapurkar N; Dakshanamurthy S; Kallakury B; Tucker RD; Kwagyan J; Smith JP
Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163821
[TBL] [Abstract][Full Text] [Related]
14. Role of FXR in Bile Acid and Metabolic Homeostasis in NASH: Pathogenetic Concepts and Therapeutic Opportunities.
Radun R; Trauner M
Semin Liver Dis; 2021 Nov; 41(4):461-475. PubMed ID: 34289507
[TBL] [Abstract][Full Text] [Related]
15. Soyasaponin A
Xiong F; Zheng Z; Xiao L; Su C; Chen J; Gu X; Tang J; Zhao Y; Luo H; Zha L
Mol Nutr Food Res; 2021 Jul; 65(14):e2100067. PubMed ID: 34047448
[TBL] [Abstract][Full Text] [Related]
16. An Intestinal Microbiota-Farnesoid X Receptor Axis Modulates Metabolic Disease.
Gonzalez FJ; Jiang C; Patterson AD
Gastroenterology; 2016 Nov; 151(5):845-859. PubMed ID: 27639801
[TBL] [Abstract][Full Text] [Related]
17. Interaction of gut microbiota with dysregulation of bile acids in the pathogenesis of nonalcoholic fatty liver disease and potential therapeutic implications of probiotics.
Chen J; Thomsen M; Vitetta L
J Cell Biochem; 2019 Mar; 120(3):2713-2720. PubMed ID: 30443932
[TBL] [Abstract][Full Text] [Related]
18. Discovery of HPG1860, a Structurally Novel Nonbile Acid FXR Agonist Currently in Clinical Development for the Treatment of Nonalcoholic Steatohepatitis.
Mo C; Xu X; Zhang P; Peng Y; Zhao X; Chen S; Guo F; Xiong Y; Chu XJ; Xu X
J Med Chem; 2023 Jul; 66(14):9363-9375. PubMed ID: 37424079
[TBL] [Abstract][Full Text] [Related]
19. Pharmacologic Modulation of Bile Acid-FXR-FGF15/FGF19 Pathway for the Treatment of Nonalcoholic Steatohepatitis.
Schumacher JD; Guo GL
Handb Exp Pharmacol; 2019; 256():325-357. PubMed ID: 31201553
[TBL] [Abstract][Full Text] [Related]
20. Transcriptome Analysis of Dual FXR and GPBAR1 Agonism in Rodent Model of NASH Reveals Modulation of Lipid Droplets Formation.
Carino A; Marchianò S; Biagioli M; Fiorucci C; Zampella A; Monti MC; Morretta E; Bordoni M; Di Giorgio C; Roselli R; Ricci P; Distrutti E; Fiorucci S
Nutrients; 2019 May; 11(5):. PubMed ID: 31117231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]